Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01948427 · ClinicalTrials.gov registry record
Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
A clinical trial, sponsored by Amgen.
- Terminated
- Registry status
- 203
- Enrollment target
NCT01948427: Clinical Trial study, sponsored by Amgen.
NCT01948427 is a clinical trial that was terminated before completion, run by Amgen. The registered enrollment target is 203 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01948427 was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- 203 participants
- Enrollment target
Study Summary
THRIVE is an observational study that will collect information on patients with UCDs. THRIVE will follow enrolled participants for up to 10 years. As an observational study, enrolled patients will not be required to make any additional office visits or take any medicine outside of normal care.
Primary Outcome
Retrospective is defined as the 12 months preceding enrollment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2013-09-25 |
| Est. Completion | 2020-02-24 |
Why NCT01948427 stopped before completion
NCT01948427 is an observational study that tracks outcomes without assigning an intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01948427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01948427 about?
NCT01948427 is a clinical study titled "Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)". THRIVE is an observational study that will collect information on patients with UCDs. THRIVE will follow enrolled participants for up to 10 years. As an observational study, enrolled patients will not be required to make any additional office visits or take any medicine outside of normal care.
What is the current status of trial NCT01948427?
This trial is currently terminated. The enrollment target is 203 participants. The study started on 2013-09-25. Estimated completion is 2020-02-24.
Who is sponsoring clinical trial NCT01948427?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI